Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1256Neoplasms 1074Carcinoma, Non-Small-Cell Lung 874Prostatic Neoplasms 714Lung Neoplasms 596Colorectal Neoplasms 590Neoplasm Metastasis 452Multiple Myeloma 432Leukemia, Myeloid, Acute 423Pancreatic Neoplasms 370Ovarian Neoplasms 367Melanoma 324Carcinoma, Hepatocellular 299Squamous Cell Carcinoma of Head and Neck 276Brain Neoplasms 275Recurrence 273Stomach Neoplasms 245Head and Neck Neoplasms 241Glioblastoma 239Carcinoma, Renal Cell 227Lymphoma 226Triple Negative Breast Neoplasms 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Urinary Bladder Neoplasms 211Uterine Cervical Neoplasms 200Endometrial Neoplasms 199Sarcoma 195Glioma 194Lymphoma, Non-Hodgkin 188

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pain, Intractable × 90 days × Clear all
NCT00804154 2026-05-01

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
45 enrolled

Cancer Pain, Pain, Intractable

NCT02522611 2026-04-13

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡